N-[5-nitro-2-furfurylidene]-3-amino-2-oxazolidinone activation by the human intestinal cell line Caco-2 monitored through noninvasive electron spin resonance spectroscopy

Molecular Pharmacology

Volumn 49, Issue 3, 1996, Pages 547-555

  Rossi, Luisa ^a   De Angelis, Isabella ^b   Pedersen, Jens Z ^c   Marchese, Eliana ^a   Stammati, Annalaura ^b   Rotilio, Giuseppe ^a   Zucco, Flavia ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; ALLOPURINOL; ANTIMYCIN A1; CARBON MONOXIDE; CHLORAL HYDRATE; CYANAMIDE; CYTOCHROME P450 REDUCTASE; DICOUMAROL; DIPHENYLIODONIUM SALT; DISULFIRAM; FREE RADICAL; FURAZOLIDONE; METYRAPONE; NITROFURAN DERIVATIVE; POTASSIUM CYANIDE; PROADIFEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROTENONE; XANTHINE OXIDASE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVATION; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTESTINE CELL; LIVER MICROSOME; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; REACTION TIME;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; BINDING SITES; BIOTRANSFORMATION; CACO-2 CELLS; CELL DIFFERENTIATION; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICALS; FURAZOLIDONE; HUMANS; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITRO COMPOUNDS; OXIDATION-REDUCTION; RATS; SPECTROPHOTOMETRY;

EID: 0030004986     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Adams, G. E., A. Breccia, E. M. Fielden, and P. Wardman, Eds. Selective Activation of Drugs by Redox Processes. Plenum Press, New York (1990).
2. Edwards, D. I. Nitroimidazole drugs: action and resistance mechanisms. I. Mechanisms of action. J. Antimicrob. Chemother. 31:9-20 (1993)
3. McCalla, D. R. Mutagenicity of nitrofuran derivatives: review. Environ. Mutagen. 5:745-765 (1983).
4. Wang C. Y., W. A. Croft, and G. T. Bryan. Tumor production in germ-free rats fed 5-nitrofurans. Cancer Lett. 21:303-308 (1984).
5. Bremner, J. C. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev. 12:177-193 (1993).
6. Mason, R. P. Free radical metabolites of toxic chemicals and drugs as sources of oxidative stress, in Biological Consequences of Oxidative Stress (L. Spatz and A. D. Bloom, eds.). Oxford University Press, New York, 23-49 (1992).
7. Rossi, L., J. M. Silva, L. G. McGirr, and P. J. O'Brien. Nitrofurantoin-mediated oxidative stress cytotoxicity in isolated rat hepatocytes. Biochem. Pharmacol. 37:3109-3117 (1988).
8. Adam, A., L. L. Smith, and G. M. Cohen. An assessment of the role of redox cycling in mediating the toxicity of paraquat and nitrofurantoin. Environ. Health Perspect. 85:113-117 (1990).
9. Peterson, F. J., R. P. Mason, J. Hovsepian, and J. L. Holtzman. Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem. 254:4009-4014 (1979).
10. Abraham, E. T., J. E. Knapp, M. B. Minnigh, L. K. Wong, M. A. Zemaitis and J. D. Alvin. Reductive metabolism of furazolidone by Escherichia coli and rat liver in vitro. Drug Metab. Dispos. 12:732-741 (1984).
11. Vroomen, L. H. M., M. C. J. Berghmans, P. J. Van Bladeren, J. P. Groten, C. J. Wissink, and H. A. Kuiper. In vivo and in vitro metabolic studies of furazolidone: a risk evaluation. Drug Metab. Rev. 22:663-676 (1990).
12. De Angelis, I., L. A. P. Hoogenboom, M. B. M. Huveneers-Oorsprong, F. Zuceo, and A. Stammati. Established cell line for safety assessment of food contaminants: differing furazolidone toxicity to V79, HEp-2 and Caco-2 cells Food Chem. Toxicol. 32:481-488 (1994).
13. Raleigh, J. A., and C. J. Koch. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40:2457-2464 (1990)
14. Rauth, A. M., R. S. Marshall, and B. L. Kuehl. Cellular approaches to bioreductive drug mechanisms. Cancer Metastasis Rev. 12:153-164 (1993).
15. Hajjar, R. J., R. Liao, J. B. Young, F. Fuleihan, M. G. Glass, and J. K. Gwathmey. Pathophysiological and biochemical characterization of an avian model of dilated cardiomyopathy: comparison to findings in human dilated cardiomyopathy. Cardiovasc. Res. 27:2212-2221 (1993).
16. Pettinger, W. A., F. G. Soyangco, and J. A. Oates. Inhibition of monoamine oxidase in man by furazolidone. Clin. Pharmacol. Ther. 2:442-447 (1968).
17. Ali, B. H. Pharmacology and toxicity of furazolidone in man and animals: some recent research. Gen. Pharmacol. 20:557-563 (1989).
18. Pinto, M , S. Robine-Leon, M.-D. Appay, M. Kedinger, N. Triadou, E. Dussaulx, B. Lacroix, P. Simon-Assmann, K. Haffen, J. Fogh, and A. Zweibaum. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47:323-330 (1983).
19. Grasset, E., M. Pinto, E. Dussaulx, A. Zweibaum, and J. F. Desjeux. Epithelial properties of human colonic carcinoma cell line Caco-2: electrical parameters. Am. J. Physiol. 247:C260-C267 (1984).
20. Grasset, E., J. Bernareu, and M. Pinto. Epithelial properties of human colonic carcinoma cell line Caco-2: effect of segretagogues. Am. J. Physiol. 248:C410-C418 (1985).
21. Hidalgo, I. J., J. T. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749 (1989).
22. Matsumoto, H., R. H. Erickson, J. R. Gum, M Yoshioka, E. Gum, and Y. S. Kim. Biosynthesis of alkaline phosphatase during differentiation of the human colon cancer cell line Caco-2. Gastroenterology 98:1199-1207 (1990).
23. Peters, W. H. N., and H. M. J. Roelofs. Time-dependent activity and expression of glutathione S-transferases in the human colon adenocarcinoma cell line Caco-2. Biochem. J. 264:613-616 (1989).
24. Oude Elferink, R. P. J., C. T. M. Bakker, and P. L. M. Jansen. Ghitathione-conjugate transport by human colon adenocarcinoma cells (Caco-2 cells). Biochem. J. 290:759-764 (1993).
25. Baker, S. S., and R. D. Baker, Jr. Caco-2 cell metabolism of oxygen-derived radicals. Dig. Dis. Sci. 38:2273-2280 (1993).
26. Boulenc, X., M. Bourne, I. Fabre, C. Roque, H. Joyeux, Y. Berger, and G. Fabre. Regulation of cytochrome P450IA1 gene expression in a human intestinal cell line, Caco-2. J. Pharmacol. Exp. Ther. 263:1471-1478 (1992).
27. Vincentini, O., I. De Angelis, A. Stammati, and F. Zucco. Functional alterations induced by the food contaminant furazolidone on the human tumoral intestinal cell line Caco-2. Toxicol. In Vitro 7:403-406 (1993).
28. Zucco, F., I. De Angelis, O. Vincentini, L. Rossi, C. Steinkühler, and A. Stammati. Potentiality of the human intestinal cell line Caco-2 in toxicological investigation. In Vitro Toxicol. 7:107-112 (1994).
29. Baker, S. S., and R. D. Baker, Jr. Antioxidant enzymes in the differentiated Caco-2 cell line. In Vitro Cell. & Dev. Biol. Anim. 28:643-647 (1992).
30. Dallner, G. Isolation of rough and smooth microsomes. Methods Enzymol. 31:191-201 (1974).
31. Borenfreund, E., and J. A. Puerner. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett. 24:119-124 (1985).
32. Strobel, H. W., and J. D. Dignam. Purification and properties of NADPH cytochrome P450 reductase. Methods Enzymol. 52:89-96 (1978).
33. 5 reductase. Proc. Am. Assoc. Cancer Res. 32:397 (1991).
34. Rosenberg, D. W., and T. Leff. Regulation of cytochrome P450 in cultured human colonie cells. Arch. Biochem. Biophys. 300:186-192 (1993).
35. Lloyd, D., and J. Z. Pedersen. Metronidazole radical anion generation in vivo in Trichomonas vaginalis: oxygen quenching is enhanced in a drug-resistant strain. J. Gen. Microbiol. 131:87-92 (1985).
36. Rao, D. N. R., S. Jordan, and R. P. Mason. Generation of nitro radical anions of some 5-nitrofurans, and 2- and 5-nitroimidazoles by rat hepatocytes. Biochem. Pharmacol. 37:2907-2913 (1988)
37. Doussier, J., and P. V. Vignais. Diphenylene iodonium as an inhibitor of the NADPH osidase complex of bovine neutrophus. Eur. J. Biochem. 208:61-71 (1992).
38. Tew, D. G. Inhibition of cytochrome P450 reductase by the diphenyliodonium cation: kinetic analysis and covalent modifications. Biochemistry 32:10209-10215 (1993).
39. Silva, J. M., and P. J. O'Brien. Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions. Br. J. Cancer 68:484-491 (1993).
40. Holtzman, J. L., D. L. Crankshaw, F. J. Peterson, and C. F. Polnaszek. The kinetics of the aerobic reduction of nitrofurantom by NADPH-cytochrome P-450 (e) reductase. Mol. Pharmacol. 20:669-673 (1981).
41. Iscan, M. Comparative studies of sheep lung and liver nitrofurantoin reductase. Comp. Biochem. Physiol. C Comp. Pharmacol. 106:579-584 (1993).
42. Goeptar, A. R., J. M. te Koppele, E. K. Lamme, J. M. Piqué, and N. P. E. Vermeulen. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol. Pharmacol. 44:1267-1277 (1993).
43. Goeptar, A. R., E. J. Groot, H. Scheerens, J. N. N. Commandeur, and N. P. E. Vermeulen. Cytotoxicity of mitomycin C and adriamycin in freshly isolated rat hepatocytes: the role of cytochrome P450. Cancer Res. 54: 2411-2418 (1994).
44. Nebert, D W., D. R. Nelson, M. J. Coon, R. W. Estabrook, R. Feyeresein, Y. Fujii-Kuriyama, F. J. Gonzalez, F. P. Guengerich, I. C. Gunsalus, E. F. Johnson, T. L Loper, R. Soto, M. R. Waterman, and D. J. Waxman. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 10:1-14 (1991)